Options in Prophylactic Surgery to Prevent Ovarian Cancer in High-Risk Women: How New Hypotheses of Fallopian Tube Origin Influence Recommendations

Gynecologic Cancers (RJ Morgan, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Gynecologic Cancers

Opinion statement

In women at increased risk of developing ovarian cancer, risk-reducing salpingo-oophorectomy is the only intervention that has been shown to decrease mortality from ovarian cancer and is the standard of care for risk reduction. Prophylactic salpingectomy with delayed oophorectomy should be considered in high-risk premenopausal women in the setting of a clinical trial.

Keywords

Salpingectomy Oophorectomy BRCA Hereditary breast and ovarian cancer syndrome Ovarian cancer Fimbriectomy 

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. 1.
    National Cancer Institute. Surveillance, epidemiology, and end results program. SEER stat fact sheets: ovary cancer. http://seer.cancer.gov/statfacts/html/ovary.html. 2015.
  2. 2.
    Walsh T, Lee MK, Casadei S, Thornston AM, Stray SM, Pennil C, et al. Detection of inherited mutations for breast and ovarian cancer using genomic capture and massively parallel sequencing. Proc Natl Acad Sci. 2010;107(28):12629–33.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Norquist BM, Harrell MI, Brady MF, Walsh T, Lee MK, Gulsuner S, et al. Inherited mutations in women with ovarian carcinoma. JAMA Oncol. 2015. doi:10.1001/jamaoncol.2015.5495.Google Scholar
  4. 4.
    Walsh T, Casadei S, Lee MK, Pennil CC, Nord AS, Thornton AM, et al. Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing. Proc Natl Acad Sci. 2011;108(44):18032–7.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    National Comprehensive Cancer Network. NCCN Guidelines version 2.2015. Hereditary breast and/or ovarian cancer syndrome. 2015.Google Scholar
  6. 6.
    American College of Obstetrics and Gynecology. ACOG practice bulletin no. 89. Elective and risk-reducing salpingo-oophorectomy. Obstet Gynecol. 2008;111(1):231–41.CrossRefGoogle Scholar
  7. 7.
    United States Preventative Services Task Force (USPSTF). BRCA-related Cancer: risk assessment, genetic counseling and genetic testing. December 2013.Google Scholar
  8. 8.
    Walker JL, Powell CB, Chen LM, Carter J, Bae Jump VL, Parker LP, et al. Society of gynecologic oncology recommendations for the prevention of ovarian cancer. Cancer. 2015;121(13):2108–20.CrossRefPubMedGoogle Scholar
  9. 9.
    Kauff ND, Domchek SM, Friebel TM, Robson ME, Lee J, Garber JE, et al. Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study. J Clin Oncol. 2008;26(8):1331–7.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Domchek SM, Friebel TM, Singer CF, Evans DG, Lynch HT, Isaacs C, et al. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA. 2010;304(9):967–75.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.•
    Finch A, Lubinski J, Moller P, Singer CF, Karlan B, Senter L, et al. Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation. J Clin Oncol. 2014;32(15):1547–53. To date, this is the largest prospective study in BRCA mutation carriers that provides risk percentages of developing ovarian cancer at certain age intervals. It also provides risk reduction estimates on ovarian cancer mortality and all-cause mortality following oophorectomy.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Iodice S, Barile M, Rotmensz N, Feroce I, Bonanni B, Radice P, et al. Oral contraceptive use and breast or ovarian cancer risk in BRCA1/2 carriers: a meta-analysis. Eur J Cancer. 2010;46:2275–84.CrossRefPubMedGoogle Scholar
  13. 13.
    Havrilesky LJ, Moorman PG, Lowery WJ, Gierisch JM, Coeytaux RR, Urrutia RP, et al. Oral contraceptive pills as primary prevention for ovarian cancer: a systemic review and meta-analysis. Obstet Gynecol. 2013;122(1):139–47.CrossRefPubMedGoogle Scholar
  14. 14.
    Buys SS, Partridge E, Black A, Johnson CC, Lamerato L, Isaacs C, et al. Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial. JAMA. 2011;305(22):2295–303.CrossRefPubMedGoogle Scholar
  15. 15.
    Lu KH, Skates S, Hernandez MA, Bedi D, Bevers T, Leeds L, et al. A 2-stage ovarian cancer screening strategy using the risk of ovarian cancer algorithm (ROCA) identifies early-stage incident cancers and demonstrates high positive predictive value. Cancer. 2013;119(9):3454–61.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.•
    Jacobs IJ, Menon U, Ryan A, Gentry-Maharaj A, Burnell M, Kalsi JK, et al. Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomized controlled trial. Lancet. 2015. doi:10.1016/S0140-6736(15)01224-6. This recently published trial shows that multimodal ovarian cancer screening using ROCA results in a mortality reduction in average risk postmenopausal women.Google Scholar
  17. 17.
    Greene MH, Piedmonte M, Alberts D, Gail M, Hensley M, Miner Z, et al. A prospective study of risk-reducing salpingo-oophorectomy and longitudinal CA-125 screening among women at increased genetic risk of ovarian cancer: design and baseline characteristics: a gynecologic oncology group study. Cancer Epidemiol Biomarkers Prev. 2008;17(3):594–604.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Rosenthal AD. Ovarian cancer screening in the high-risk population—the UK Familial Ovarian Cancer Screening Study (UKFOCSS). Int J Gynecol Cancer. 2012;22(1):27–8.CrossRefGoogle Scholar
  19. 19.
    Shuster LT, Rhodes DJ, Gostout BS, Grossardt BR, Rocca WA. Premature menopause or early menopause: long-term health consequences. Maturitas. 2010;65(2):161–6.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Faubion SS, Kuhle CL, Shuster LT, Rocca WA. Long-term health consequences of premature or early menopause and considerations for management. Climacteric. 2015;18(4):483–91.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Johansen N, Liavaag AH, Tanbo TG, Dahl AA, Pripp AH, Michelsen TM. Sexual activity and functioning after risk-reducing salpingo-oophorectomy: impact of hormone replacement therapy. Gynecol Oncol. 2016;140(1):101–6.CrossRefPubMedGoogle Scholar
  22. 22.
    Rebbeck TR, Friebel T, Wagner T, Lynch HT, Garber JE, Daly MB, et al. Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE study group. J Clin Oncol. 2005;23(31):7804–10.CrossRefPubMedGoogle Scholar
  23. 23.
    Li HX, Lu ZH, Shen K, Cheng WJ, Malpica A, Zhang J, et al. Advances in serous tubal intraepithelial carcinoma: correlation with high grade serous carcinoma and ovarian carcinogenesis. Int J Clin Exp Pathol. 2014;7(3):848–57.PubMedPubMedCentralGoogle Scholar
  24. 24.
    Piek JM, van Diest PJ, Zweemer RP, Jansen JW, Poort-Keesom RJ, Menko FH, et al. Dysplastic changes in prophylactically removed fallopian tubes of women predisposed to developing ovarian cancer. J Pathol. 2001;195(4):451–6.CrossRefPubMedGoogle Scholar
  25. 25.
    Przybycin CG, Kurman RJ, Ronnett BM, Shih IM, Vang R. Are all pelvic (nonuterine) serous carcinomas of tubal origin? Am J Surg Pathol. 2010;34(10):1407–16.CrossRefPubMedGoogle Scholar
  26. 26.
    Holman LL, Friedman S, Daniels MS, Sun CC, Lu K. Acceptability of prophylactic salpingectomy with delayed oophorectomy as risk-reducing surgery among BRCA mutation carriers. Gynecol Oncol. 2014;133(2):283–6.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Hankinson SE, Hunter DJ, Colditz GA, Willett WC, Stampfer MJ, Rosner B, et al. Tubal ligation, hysterectomy, and risk of ovarian cancer: a prospective study. JAMA. 1993;270(23):2813–8.CrossRefPubMedGoogle Scholar
  28. 28.
    Cibula D, Widschwendter M, Majek O, Dusek L. Tubal ligation and the risk of ovarian cancer: review and meta-analysis. Hum Reprod Update. 2011;17(1):55–67.CrossRefPubMedGoogle Scholar
  29. 29.
    Rice MS, Murphy MA, Tworoger SS. Tubal ligation, hysterectomy and ovarian cancer: a meta-analysis. J Ovarian Res. 2012;5(1):13.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Lessard-Anderson CR, Handlogten KS, Molitor RJ, Dowdy SC, Cliby WA, Weaver AL, et al. Effect of tubal sterilization technique on risk of serous epithelial ovarian and primary peritoneal carcinoma. Gynecol Oncol. 2014;135(5):423–7.CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Rice MS, Hankinson SE, Tworoger SS. Tubal ligation, hysterectomy, unilateral oophorectomy, and risk of ovarian cancer in the nurses’ health studies. Fertil Steril. 2014;102(1):192–98.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Madsen C, Baandrup L, Dehlendorff C, Kjaer SK. Tubal ligation and salpingectomy and the risk of epithelial ovarian cancer and borderline ovarian tumors: a nationwide case-control study. Acta Obstet Gynecol Scand. 2015;94(1):86–94.CrossRefPubMedGoogle Scholar
  33. 33.
    Beard CM, Hartmann LC, Atkinson EJ, O’Brien PC, Malkasian GD, Keeney GL, et al. The epidemiology of ovarian cancer: a population-based study in Olmsted County, Minnesota, 1935–1991. Ann Epidemiol. 2000;10(1):14–23.CrossRefPubMedGoogle Scholar
  34. 34.•
    Falconer H, Yin L, Gronberg H, Altman D. Ovarian cancer risk after salpingectomy: a nationwide population-based study. J Natl Cancer Inst. 2015; 107(2). doi: 10.1093/jnci/dju410. This study provides evidence of the ovarian cancer risk reduction following bilateral salpingectomy in average-risk women.
  35. 35.
    Arts-de Jong M, Harmsen MG, Hoogerbrugge N, Massuger LF, Hermens RP, de Hulla JA. Risk-reducing salpingectomy with delayed oophorectomy in BRCA 1/2 mutation carriers: patients’ and professionals’ perspectives. Gynecol Oncol. 2015;136(2):305–10.CrossRefPubMedGoogle Scholar
  36. 36.
    Chandrasekaran D, Menon U, Evans G, Crawford R, Saridogan E, Jacobs C, et al. Risk reducing salpingectomy and delayed oophorectomy in high risk women: views of cancer geneticists, genetic counsellors, and gynecologic oncologists in the UK. Fam Cancer. 2015;14(4):521–30.CrossRefPubMedGoogle Scholar
  37. 37.
    Kwon JS, Tinker A, Pansegrau G, McAlpine J, Housty M, McCullum M, et al. Prophylactic salpingectomy and delayed oophorectomy as an alternative for BRCA mutation carriers. Obstet Gynecol. 2013;121(1):14–21.CrossRefPubMedGoogle Scholar
  38. 38.
    Centre Oscar Lambret. Radical fimbriectomy for young BRCA mutation carriers. https://clinicaltrials.gov/ct2/show/NCT01608074?term=NCT01608074&rank=1. 2015.
  39. 39.
    University Medical Center Nijmegen. Early salpingectomy (tubectomy) with delayed oophorectomy in BRCA 1/2 gene mutation carriers (TUBA). https://clinicaltrials.gov/ct2/show/NCT02321228?term=NCT02321228&rank=1. 2015.
  40. 40.
    M.D. Anderson Cancer Center. Prophylactic salpingectomy with delayed oophorectomy. https://clinicaltrials.gov/ct2/show/NCT01907789?term=NCT01907789&rank=1. 2015.

Copyright information

© Springer Science+Business Media New York 2016

Authors and Affiliations

  1. 1.Department of Obstetrics and Gynecology, Division of Gynecologic SurgeryMayo ClinicRochesterUSA

Personalised recommendations